Building on the success demonstrated by temelimab in clinical trials for multiple sclerosis, the anti-HERV-K-env monoclonal antibody represents a potential paradigm shift in ALS treatment, specifically addressing pathogenic mechanisms previously untargeted by conventional therapies. This evidence concerns the gene ERVW-1 and amyotrophic lateral sclerosis.